Literature DB >> 1697447

Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate.

A F List1, T D Kummet, J D Adams, H G Chun.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697447     DOI: 10.1016/0002-9343(90)90358-k

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  7 in total

1.  Lysis pneumonopathy associated with the use of fludarabine phosphate.

Authors:  J J Crowley; L Knight; N Charan
Journal:  West J Med       Date:  1994-12

Review 2.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 3.  Management of chronic lymphocytic leukaemia.

Authors:  N Kalil; B D Cheson
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

Review 4.  Achieving optimal outcomes in chronic lymphocytic leukaemia.

Authors:  T J Hamblin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

6.  Tumour lysis syndrome after treatment of chronic lymphocytic leukaemia with fludarabine.

Authors:  C Montalban; F Liaño; A Aguilera
Journal:  Postgrad Med J       Date:  1994-09       Impact factor: 2.401

7.  Renal failure in a patient with chronic lymphocytic leukaemia treated with fludarabine.

Authors:  M P Macheta; L A Parapia; D R Gouldesbrough
Journal:  J Clin Pathol       Date:  1995-02       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.